OM1 expands real-world data to help advance Parkinson’s research
The company launched its dataset on Parkinson's disease in 2023
OM1 has expanded a real-world dataset of people with neurological conditions, including Parkinson’s disease, adding health records and clinical notes for 500,000 more people.
“Expanding our neurology network to more than 3 million patients represents a pivotal milestone in enabling better outcomes for neurology patients,” Carl Marci, MD, chief clinical officer and managing director of mental health and neuroscience at OM1, said in a company press release.
By curating large datasets and providing analysis tools, including artificial intelligence (AI) insights, OM1 hopes to make it easier for scientists to innovate in healthcare.
Parkinson’s, which is estimated to affect more than 10 million people worldwide, is a progressive neurological disorder marked by both motor and nonmotor symptoms. The underlying causes of brain damage in the disease aren’t entirely understood, but genetics and environmental exposures are thought to play a role. Available treatments can help ease symptoms and manage the disease, but there is no cure.
Analyzing large-scale, real-world data from people with Parkinson’s may help researchers better understand the disease’s causes, early signs, and its progression, along with how people respond to different therapies. Researchers may be able to leverage this understanding to develop new strategies for care and therapies, including personalized medical interventions.
Expanding data adds to research, treatment options
OM1 seeks to provide this type of data, along with tools to help researchers use the information efficiently.
Features of OM1’s neurology data include a large number of records, including clinical results, insurance claims, specialist notes, and treatment information. The records also reflect social determinants of health, such as economic status, which may influence exposure to toxic chemicals and other neurological risk factors.
The company’s Mental Health & Neuroscience data network, which was launched in 2022, involves more than 2,500 specialty doctors and more than 3,000 specialty practices in the U.S., and contains several disease-specific datasets.
The Parkinson’s disease dataset, which was launched in 2023, includes more than 878,000 patients, with more than 7,000 having available health records over a mean follow-up of nine years. This may help researchers track disease development and compile long-term data about responses to specific treatments.
Patient records in these datasets also link to other OM1 networks, including primary care and mental health.
“This captures a more complete view of each patient journey from early symptoms through diagnosis and ongoing treatment, empowering stakeholders to conduct more comprehensive and impactful studies,” the release states.
Along with analysis and data visualization capabilities, OM1 also provides AI insights into data.
“By integrating deep clinical data and advanced AI, we’re equipping researchers and healthcare providers with powerful tools to uncover new insights into disease progression, treatment response, and more personalized care in complex neurological conditions,” Marci said.
OM1’s neurology network also includes data on Alzheimer’s disease and multiple sclerosis. The company is also growing datasets related to migraines and amyotrophic lateral sclerosis, or ALS.
About the Author
